SR9009: A Literature Course in Six Modules

This course summarises what the published literature reports about SR9009 (also written stenabolic), organised into six modules. It describes studies, models and endpoints as they were reported, and marks clearly where evidence is thin or absent. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or compound.

Module 1 — What SR9009 Is and How It Has Been Studied

Definition and class

SR9009 is a synthetic, low-molecular-weight organic compound described in the nuclear-receptor pharmacology literature as an agonist of the REV-ERB receptors, REV-ERBα (gene symbol NR1D1) and REV-ERBβ (NR1D2). These receptors are transcriptional repressors embedded in the core molecular circadian clock. Work published in Nature examined pharmacological activation of REV-ERBs and reported that it was lethal in cancer cells and in cells undergoing oncogene-induced senescence, using the REV-ERB agonists developed in that research programme (PMID 29320480).

Why "SR9009 peptide" is a category error

SR9009 is not a peptide. Peptides are short chains of amino acids joined by peptide bonds; SR9009 is a small synthetic molecule with no amino-acid backbone. It is grouped with peptides in informal discussion because both are frequently encountered as research-use-only chemicals rather than approved medicines, but structurally and pharmacologically they belong to different classes. SR9009 acts on an intracellular nuclear receptor, a mechanism described across the REV-ERB literature, including work on Rev-erb control of cholesterol synthesis (PMID 28213272).

How it has been studied

The literature relevant to SR9009 falls into three overlapping groups. First, studies that administered a REV-ERB agonist to cells or animals, such as the cancer and senescence work in Nature (PMID 29320480) and a study of pharmacological Rev-erbα activation in a doxorubicin-induced cardiotoxicity model that implicated PGC-1α signalling (PMID 36874248). Second, studies that manipulated REV-ERB genetically to define what the receptor does, such as work reporting that Rev-erbα regulates neuroinflammation (PMID 30792350). Third, broader circadian-clock studies that establish the biological context, including genetic disruption of Bmal1 in the intestinal epithelium, which researchers reported reduced colonic inflammation (PMID 40307620).

Limits of the evidence in Module 1

The verified record underpinning this course is preclinical. It contains cell-culture and rodent work and no human trials of SR9009. Several papers characterise the receptor rather than the compound, and findings from genetic models do not automatically transfer to a drug-like agonist. Where a paper described "pharmacological activation" of REV-ERB without SR9009 being the sole agent, that distinction matters and is flagged throughout.

Module 2 — Mechanism as Described in the Literature

REV-ERBα and REV-ERBβ sit on the repressive arm of the transcription–translation feedback loop that generates circadian rhythms. Because they repress clock and clock-output genes, activating them is expected to shift the timing and amplitude of downstream transcriptional programmes. The consequences reported in the literature are tissue-specific.

• Lipid and cholesterol pathways. A pharmacology paper examined Rev-erb regulation of cholesterologenesis, linking receptor activity to the cholesterol-synthesis programme (PMID 28213272). Separately, researchers reported that the clock-targeting compound nobiletin promoted lipolysis of white adipose tissue in a circadian-clock-dependent manner, illustrating that clock-directed pharmacology can alter fat metabolism (PMID 39094217).
• Energy metabolism and the clock. Genetic work reported that deficiency of intestinal Bmal1 prevented obesity induced by high-fat feeding in mice, showing that clock-gene manipulation in a single tissue can change whole-body metabolic outcomes (PMID 34493722).
• Innate immunity. A PNAS study reported that the circadian clock protein Rev-erbα regulates neuroinflammation (PMID 30792350), and later work reported that Nr1d1 regulated microglial M1/M2 polarisation in a traumatic brain injury model (PMID 41296614). A review of monocyte and macrophage clocks described disruption of their molecular circadian clock in allergic inflammation (PMID 38863703).
• Adaptive immunity. Researchers reported that REV-ERBα regulates T_H17 cell development and autoimmunity, placing the receptor upstream of a key inflammatory T-cell lineage (PMID 30590045).
• Tumour immunology. A cancer-biology study reported that NR1D1 stimulated antitumor immune responses in breast cancer by activating cGAS–STING signalling (PMID 37395684).

Limits of the evidence in Module 2

Mechanistic breadth is not the same as predictability. The same receptor was reported to influence tumour-cell survival (PMID 29320480), T-cell differentiation (PMID 30590045) and microglial phenotype (PMID 41296614), which means a systemic agonist would act on many tissues at once. None of these papers established which effect dominates in an intact organism, and off-target activity of small-molecule agonists is a recurring caveat in nuclear-receptor pharmacology.

Module 3 — Reported Outcomes by Study

The table below lists models, endpoints and reported results. It is a map of what was measured, not a list of benefits; no outcome below has been shown in humans.

Limits of the evidence in Module 3

Every row is a preclinical endpoint. Cell-line lethality, rodent cardiac injury markers and glial polarisation are surrogate measures, not clinical outcomes, and short experiments in disease-specific models cannot speak to healthy organisms or to long-term exposure. Two of the rows describe genetic deletions rather than drug administration, and one describes a different compound (nobiletin) included only to illustrate clock-dependent metabolic pharmacology (PMID 39094217). None of the studies reported performance, body-composition or endurance outcomes in people.

Module 4 — SR9009 Side Effects: What Studies Report

There is no human adverse-event dataset for SR9009 in the verified literature for this page. What the published record does contain are observations from cells and animals that bear on safety questions.

• Cytotoxicity is an intrinsic property of REV-ERB agonism in some cells. The Nature study reported that pharmacological activation of REV-ERBs was lethal in cancer cells and in oncogene-induced senescence, meaning cell death was the measured effect rather than an incidental finding (PMID 29320480).
• Immune programming is altered. Researchers reported that REV-ERBα regulates T_H17 cell development and autoimmunity (PMID 30590045), and that Rev-erbα regulates neuroinflammation (PMID 30792350). Because immune modulation can be favourable or unfavourable depending on context, these findings describe a liability as much as an opportunity.
• Tumour-immunity effects run in more than one direction. One study reported NR1D1 stimulated antitumor immune responses through cGAS–STING signalling in breast cancer (PMID 37395684), while the senescence findings show the same pathway can kill non-malignant senescent cells (PMID 29320480), so net effects on tissue biology were not resolved.
• Lipid pathways are engaged. Rev-erb activity was reported to regulate cholesterologenesis, which places cholesterol synthesis among the systems a REV-ERB agonist would touch (PMID 28213272).
• Vascular and glial rhythms shift. Pharmacological modulation of circadian rhythms was reported to alter rhythms in brain microvasculature (PMID 41355044), and clock-linked changes in microglial M1/M2 polarisation were reported after traumatic brain injury (PMID 41296614).
• Clock disruption has broad phenotypic consequences. Genetic studies reported that disrupting Bmal1 in intestinal epithelium reduced colonic inflammation (PMID 40307620) and that intestinal Bmal1 deficiency prevented diet-induced obesity (PMID 34493722), while a 2024 review described a disrupted monocyte and macrophage clock in allergic inflammation (PMID 38863703). Altering clock machinery therefore changes multiple systems simultaneously.

Limits of the evidence in Module 4

None of the cited papers was a safety or toxicology trial, none reported a structured adverse-event table, and none involved human participants. Absence of reported harm in a mechanistic experiment is not evidence of safety, and effects observed in engineered cell lines or disease-model animals may not correspond to what happens in intact human physiology. There is no published information in this set on interactions with medicines, on effects during pregnancy, or on long-term exposure.

Module 5 — Pharmacokinetics: Where Data Exist

Pharmacokinetics describes absorption, distribution, metabolism and excretion — how much of a compound reaches circulation, how long it persists, and what the body converts it into. The verified literature assembled for this course does not include a pharmacokinetic study of SR9009: no paper listed here was designed to measure bioavailability, plasma half-life, tissue distribution, metabolite identity or clearance, and no such parameters are quoted on this page because none of the cited papers reported them.

What can be said from the record is narrower. The studies that administered REV-ERB agonists in vivo, such as the cardiotoxicity model (PMID 36874248) and the cancer and senescence work (PMID 29320480), reported downstream biological endpoints rather than exposure–response modelling. Circadian pharmacology adds a further variable: because REV-ERB target-gene expression oscillates across the day, the timing of administration relative to the animal's internal clock can influence measured effects, a theme running through work on clock-dependent lipolysis (PMID 39094217) and on pharmacologically modulated vascular rhythms (PMID 41355044).

Limits of the evidence in Module 5

This module is defined mainly by what is missing. Without published human or animal pharmacokinetic parameters in the verified set, no exposure estimate, dosing interval or route comparison can be derived, and any figure circulating elsewhere is outside the scope of the papers cited here. Doses used in individual experiments are not reproduced on this page, because the cited abstracts are the boundary of what this course can support.

Module 6 — Regulatory Status, Stated Factually

The following are administrative facts, not findings, and they change over time.

1. No approved product. SR9009 is not an active ingredient in any medicine approved by the US Food and Drug Administration, the European Medicines Agency or comparable national regulators. There is no approved label, no approved indication and no regulator-reviewed safety summary for it.
2. Research-use-only supply. Material bearing the name SR9009 is distributed in the chemical-supply channel labelled for laboratory research use only and not for human or veterinary use. Research-use-only labelling means a product has not undergone regulatory review for human administration.
3. Dietary supplements. Investigational drug substances that have never been approved are not lawful dietary-supplement ingredients in the United States; FDA has repeatedly stated that selective androgen receptor modulators and similar unapproved research compounds do not meet the statutory definition of a dietary ingredient.
4. Compounding. US pharmacy compounding under sections 503A and 503B is generally limited to substances that are components of approved drugs, appear in an applicable USP monograph, or are on an FDA bulk-substances list. A substance meeting none of those criteria is not eligible for compounding, and SR9009 has no approved product or FDA bulk-list entry underpinning such eligibility.
5. Sport. The World Anti-Doping Agency publishes an annually updated Prohibited List that includes REV-ERB (Rev-Erbα) agonists, with SR9009 named as an example, within its metabolic-modulator category. Athletes in WADA-code sports are subject to that list.

This is general regulatory information, not legal advice; rules differ by country and state and are revised frequently.

Limits of the evidence in Module 6

Regulatory classification says nothing about biological activity, and biological activity in a mouse says nothing about regulatory acceptability. Neither substitutes for the other. Listings and guidance documents are also amended without notice, so the primary sources — regulator databases and the current Prohibited List — are the authoritative references.

What the Studies Did Not Test

Reading the verified record end to end, several gaps are conspicuous:

• Healthy humans. No paper cited here enrolled human participants, so no human efficacy, tolerability or dose–response data exist within this set.
• Exercise capacity and body composition. None of the cited studies measured endurance, strength, lean mass or fat mass in people; the metabolic findings available are genetic mouse models (PMID 34493722) or a different clock-targeting compound in adipose tissue (PMID 39094217).
• Long-term exposure. The studies were short, mechanism-focused experiments; chronic administration, reversibility and cumulative effects were not addressed in the cited work.
• Pharmacokinetics. As set out in Module 5, no cited paper characterised absorption, half-life or metabolism.
• Special populations and interactions. Pregnancy, paediatric and geriatric physiology, hepatic or renal impairment, and drug–drug interactions were outside the scope of every paper listed.
• Comparative questions. No cited study compared a REV-ERB agonist with an established therapy for any of the conditions modelled, including the cardiotoxicity setting (PMID 36874248).

The honest summary is that SR9009 belongs to an active area of circadian pharmacology in which the receptor target is well described and the compound itself remains preclinical. Statements about what it does in humans are extrapolations, not findings. This page is educational only and is not medical advice; a licensed physician is the appropriate source for individual guidance.

References

• Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence (Nature, 2018)
• Rev-erb regulation of cholesterologenesis (Biochemical Pharmacology, 2017)
• Pharmacological Activation of Rev-erbα Attenuates Doxorubicin-Induced Cardiotoxicity by PGC-1α Signaling Pathway (Cardiovascular Therapeutics, 2023)
• Circadian clock protein Rev-erbα regulates neuroinflammation (PNAS, 2019)
• REV-ERBα Regulates T(H)17 Cell Development and Autoimmunity (Cell Reports, 2018)
• NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS-STING Signaling (Cancer Research, 2023)
• Nr1d1 Regulates Microglia M1/M2 Polarization to Alleviate Neuroinflammation after Traumatic Brain Injury (ACS Chemical Neuroscience, 2025)
• Pharmacological modulation of circadian rhythms in brain microvasculature (Journal of Cerebral Blood Flow and Metabolism, 2026)
• Nobiletin promotes lipolysis of white adipose tissue in a circadian clock-dependent manner (The Journal of Nutritional Biochemistry, 2024)
• Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feeding (Nature Communications, 2021)
• Genetic disruption of the circadian gene Bmal1 in the intestinal epithelium reduces colonic inflammation (EMBO Reports, 2025)
• The disrupted molecular circadian clock of monocytes and macrophages in allergic inflammation (Frontiers in Immunology, 2024)